You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Researchers are hoping to make the technology a success for the environment and human health while avoiding the biases that resulted from the debate over GMOs.
Synthego has developed an off switch for CRISPR by engineering a guide RNA that can be controlled through exposure to UV light.
FASMAC provides food analysis and biotech products and services, including DNA/RNA synthesis, DNA sequencing, food testing, and genetic analysis reagents.
Emmanuelle Charpentier and Jennifer Doudna have won this year's Nobel Prize in Chemistry for their work developing the CRISPR gene editing tool, according to Reuters.
The company's approach combines whole-genome sequencing, CRISPR, liquid biopsy, and gene therapy to target cancer cells with gene fusions.
Applied StemCell, based in the San Francisco Bay Area, will develop and sell CRISPR-based services and reagents under a license from ERS Genomics.
The ruling is the latest decision in the fight between the Broad and the University of California for control over the bulk of the IP rights to CRISPR-Cas9.
An international committee finds genome editing is not yet ready to be used on human embryos.
The panel also said that if any nation does decide to allow germline genome editing, its use should be limited to preventing serious monogenic diseases.
In Science this week: 29 widespread antiviral gene cassettes uncovered, and more.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.
CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.
According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.
In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.